BACKGROUND
Composite scores such as Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), EPSILoN, Pan Immune-Inflammation Value (PIV) and Systemic Immune-Inflammation Index (SII) have shown prognostic value in solid tumors, but evidence in extensive-stage small-cell lung cancer (ES-SCLC) are l...
Teresa Beninato, Giulia Stasi, G. Montelatici et al.· Tumori· 0 citations
Surgical innovation and oncologic practice are evolving rapidly. However, the evidence base supporting many interventions/decisions in surgical oncology remains vulnerable to bias, limited generalizability, and inconsistent reporting. To address this gap, this multidisciplinary review, developed through structured disc...
A. Gronchi, G. Bogani, R. Agresti et al.· European Journal of Surgical...· 0 citations
In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.
A. Prelaj, V. Mišković, Matteo Sacco et al.· Nature Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.